Dermata Therapeutics, Inc.
DRMA
$1.21
-$0.02-1.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.38% | 41.49% | 12.40% | 2.08% | -9.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.38% | -36.82% | -37.88% | -21.32% | 4.14% |
| Operating Income | 18.38% | 36.82% | 37.88% | 21.32% | -4.14% |
| Income Before Tax | 18.98% | 38.00% | 38.49% | 21.50% | -5.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.98% | 38.00% | 38.49% | 21.50% | -5.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.98% | 38.00% | 38.49% | 21.50% | -5.22% |
| EBIT | 18.38% | 36.82% | 37.88% | 21.32% | -4.14% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 87.36% | 92.84% | 93.36% | 91.51% | 86.27% |
| Normalized Basic EPS | 87.36% | 92.84% | 93.36% | 91.51% | 86.27% |
| EPS Diluted | 87.36% | 92.84% | 93.36% | 91.51% | 86.27% |
| Normalized Diluted EPS | 87.36% | 92.84% | 93.36% | 91.51% | 86.27% |
| Average Basic Shares Outstanding | 391.78% | 550.65% | 505.14% | 872.03% | 1,134.10% |
| Average Diluted Shares Outstanding | 391.78% | 550.65% | 505.14% | 872.03% | 1,134.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |